Japanese company profile · 4883
Modalis Therapeutics Corporation
In its FY2025 public filing, Modalis Therapeutics Corporation reports Gene Therapy Drug Development Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社モダリス
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
- Company profit
- −¥2.21B ↗ FY2025 · fiscal year ended December 2025
What does this company do?
What does this company do?
Not disclosed or not safely comparable in the available filings.
FY2025 · fiscal year ended December 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Gene Therapy Drug Development Business | — | — | −¥2.21B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Gene Therapy Drug Development Business
- 遺伝子治療薬開発事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Gene Therapy Drug Development Business
- 遺伝子治療薬開発事業
- Sales
- 売上高
- Operating profit
- 営業利益
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XSHO
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.